Avecho Biotechnology
- Short interest
- 0.00%
- −0.12 pp 30d
- as of 10 Feb 2025
- Reported shorts
- 29.6K
- Shares on issue
- 3.169B
Avecho Biotechnology (AVE) financials
Results, ratios and statements
Latest result
Half year to 30 Jun 2026 (HY26), figures in AUD, the reporting currency · Company filing, 26 Aug 2026
- Revenue
- n/avs n/a
- NPAT
- −$1.9MF (source: Company filing (extracted))vs n/a
- Company filing (extracted), as at 14 Oct 2026
- EPS (basic)
- n/avs n/a
- Rev YoY
- +9.9%FY
- EPS YoY
- n/aTTM
- Company filing (extracted)
Summary of Appendix 4D and Half-year Financial Report, 26 Aug 2026
Avecho Biotechnology's half-year revenue plunged 89.4% to $59,602, while its net loss narrowed 28.1% to $1,923,629. No dividend was declared. The company is progressing its Phase III insomnia trial after a positive interim review, with plans to complete participant recruitment within about 12 months.
Automated summary of the filing; the filing itself is the record.
Key ratios
12 months to 30 Jun 2026 (TTM); balance sheet at 31 Dec 2025, 6 months before; prices to 14 Oct 2026
- Gross margin
- 73.1%
- Operating margin
- −810.7%
- Net margin
- −493.6%
- FCF margin
- −468.9%
- ROE
- −151.7%
- ROA
- −60.6%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $4.7M
- Net debt / EBITDA
- n/a
- Current ratio
- 10.0×
- Interest cover
- −13.6×
- Cash dividends paid / net profit
- n/a
- Market cap
- $47.8M
- P/E
- n/a
- P/B
- 30.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | TTM Jun 26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | $742.3K | $1.2M | $1.1M | $473.6K | $1.2M |
| Gross profit | $542.6K | $895.7K | $671.9K | −$43.8K | $870.0K |
| Operating income | −$6.0M | −$6.0M | −$5.0M | −$4.8M | −$3.0M |
| EBITDA | −$3.1M | −$3.8M | −$2.9M | −$3.2M | −$2.1M |
| EBIT | −$3.2M | −$4.0M | −$3.1M | −$3.4M | −$2.3M |
| Interest expense | $441.9K | $461.4K | $57.1K | $15.4K | $6.3K |
| Pretax income | −$3.7M | −$4.4M | −$3.1M | −$3.4M | −$2.3M |
| Tax | $0 | $0 | $0 | $0 | $0 |
| NPAT | −$3.7M | −$4.4M | −$3.1M | −$3.4M | −$2.3M |
| Net interest income | −$432.2K | −$452.1K | $4.5K | $20.2K | −$2.0K |
| EPS basic | −$0.001 | −$0.001 | −$0.001 | −$0.002 | −$0.001 |
| EPS diluted | −$0.001 | −$0.001 | −$0.001 | −$0.002 | −$0.001 |
| Shares | n/a | 3.67B | 3.17B | 3.17B | 1.84B |
Financial reports
The company's own filings, newest first
- Appendix 4D and Half-year Financial ReportHalf Year Results26 Aug 2026via asx_announcements
Figures above come from this filing
- June 2026 Quarterly Activities Report & Appendix 4CQuarterly Report29 Jul 2026via asx_announcements
- March 2026 Quarterly Activities Report & Appendix 4CQuarterly Report29 Apr 2026via asx_announcements
- Annual Report 31 December 2025Annual Report27 Feb 2026via asx_announcements
- December 2025 Quarterly Activities Report & Appendix 4CQuarterly Report29 Jan 2026via asx_announcements
- Notice of Annual General Meeting 2025Financial Report31 Dec 2025via crawler
- September 2025 Quarterly Activities Report & Appendix 4CQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4D and Half-year Financial ReportHalf Year Results28 Aug 2025via asx_announcements
- June 2025 Quarterly Activities Report & Appendix 4CQuarterly Report30 Jul 2025via asx_announcements
- March 2025 Quarterly Activities Report & Appendix 4CQuarterly Report30 Apr 2025via asx_announcements
Showing 10 of 28 reports